Company / Current Liabilities
UroGen Pharma Ltd. Current Liabilities History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$46.4M
FY2025
5-year range
$22.4M / $46.4M
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
#147 of 213
Health Care
What the data says
At $46M, UroGen Pharma Ltd.'s current liabilities ranks #67 of 213 in the Health Care sector. Current Liabilities has increased for 8 consecutive years, from $7M in FY2017 to $46M in FY2025.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +16.7%.
Increased from $31M to $46M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +24.7%
- 5-Year CAGR
- +16.7%
- 10-Year CAGR
- -
Sector benchmark
#67 of 213 in Health CareTop 31% of 213This company $46.4M Sector average $1.6B
▼
-97.1% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s current liabilities has grown for 8 consecutive years.
- 5-year CAGR of +16.7%, indicating consistent growth.
- In FY2025, current liabilities increased 1.0% year-over-year.
- Ranks #147 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $46.4M | +1.0% |
| FY2024 | $45.9M | +47.2% |
| FY2023 | $31.2M | +30.5% |
| FY2022 | $23.9M | +6.9% |
| FY2021 | $22.4M | +4.4% |
| FY2020 | $21.4M | +10.0% |
| FY2019 | $19.5M | +44.7% |
| FY2018 | $13.5M | +91.4% |
| FY2017 | $7.0M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026